India Caps Cancer Drug Margins At 30% of MRP

The government decided to cap trade margins on non-scheduled anti-cancer medicines at 30% of Maximum Retail Price (MRP).

The measure applies to non-scheduled anti-cancer drugs sold across India.

The cap is expected to lower medicine prices by up to 70% and generate annual savings of ₹2,500 crore for patients.

Financial firm Jefferies reported that the healthcare sector may offset the margin cap through cost cuts and procedure price hikes.

Industry representatives are seeking uniform pricing rules across the sector.

For Indian-origin families supporting parents undergoing oncology care in India, retail medicine costs may decrease by up to 70%, though hospital procedure charges could rise.